The grades of seven pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
NuPathe Inc.’s (PATH) grade is moving up to a B (“buy”) this week from last week’s C (“hold”). NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.
GW Pharmaceuticals PLC Sponsored ADR (GWPH) boosts its rating from a C to a B this week. For more information, get Portfolio Grader’s complete analysis of GWPH stock.
Watson Pharmaceuticals (WPI) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
Paratek Pharmaceuticals Inc (PRTK) shows solid improvement this week. The company’s rating rises from a B to an A. For more information, get Portfolio Grader’s complete analysis of PRTK stock.
This is a strong week for Pain Therapeutics, Inc. (PTIE). The company’s rating climbs to A from the previous week’s B. Pain Therapeutics develops safer or more efficacious drugs for use in pain management, particularly in the area of opioid painkillers. For more information, get Portfolio Grader’s complete analysis of PTIE stock.
This week, Cardiome Pharma (CRME) pushes up from a C to a B rating. Cardiome Pharma focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. For more information, get Portfolio Grader’s complete analysis of CRME stock.
The rating of AbbVie, Inc. (ABBV) moves up this week, rising from a C to a B. AbbVie, a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. For more information, get Portfolio Grader’s complete analysis of ABBV stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
